Alnylam Pharmaceuticals, Inc. (ALNY) Posts Wider than Expected Q2 Loss
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $266.11 +0.61%
EPS Growth %: -39.0%
Financial Fact:
Other (expense) income: 229K
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -39.0%
Financial Fact:
Other (expense) income: 229K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) reported Q2 EPS of ($0.25), $0.06 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $20.9 million versus the consensus estimate of $20.81 million.
For earnings history and earnings-related data on Alnylam Pharmaceuticals, Inc. (ALNY) click here.
For earnings history and earnings-related data on Alnylam Pharmaceuticals, Inc. (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Computacenter Plc. (CCC:LN) PT Raised to GBP60 at JPMorgan
- BlackRock’s Rosenberg says inflation data key after jobs beat
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
